Abstract: Premature birth, defined as birth before 37 weeks completed gestation, represents 11.1% of all live births worldwide and the rate has increased in almost all countries over the past few decades (Dhillon et al., 2018). Although mortality after preterm birth has fallen steadily over time, preterm infants continue to have very high rates of neurodevelopmental disability, including severe motor disorders such as cerebral palsy (Dhillon et al., 2018; Yates et al., 2021). Currently there are no standard clinical neuroprotection treatments for preterm brain injury or impaired neurodevelopment. Development of treatments is a significant challenge given that the etiology is multifactorial and potentially synergistic in nature. Preterm birth itself acts as an intersect between potential adverse antenatal and postnatal factors including acute and/or chronic hypoxia and inflammation and clinical treatments such as antenatal steroids, with post-natal cardio-respiratory compromise, ventilation, infection, and ongoing clinical drug treatments including anticonvulsants, analgesics and postnatal corticosteroids (Bennet et al., 2018; Dhillon et al., 2018; Yates et al., 2021). Compounding this is the impact of injury on the stage of neural maturation leading to greater impaired neurodevelopment (Dhillon et al., 2018; Yates et al., 2021).